# Rheumatology Enrollment Form
# Medications A
**(Actemra® )**

**Fax Referral To:** 1-877-232-5455
**Address:** 500 Ala Moana Blvd., Ste 1-A Honolulu, HI 96813
**Phone:** 1-800-896-1464

**Six Simple Steps to Submitting a Referral**

## 1 PATIENT INFORMATION *(Complete or include demographic sheet)*

Patient Name: ____________________ Address: ____________________ City, State, ZIP: ____________________

Preferred Contact Methods: ☐ Phone (to primary # provided below) ☐ Text (to cell # provided below) ☐ Email (to email provided below)

*Note: Carrier charges may apply. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.*

Primary Phone: ______________ Alternate Phone: ______________ DOB: ______________ Gender: ☐ Male ☐ Female

Email: ______________________ Last Four of SSN: ______________ Primary Language: ______________

## 2 PRESCRIBER INFORMATION

Prescriber's Name: ______________________ State License #: ______________________

NPI #: ____________ DEA #: ____________ Group or Hospital: ______________________

Address: ______________________ City, State, ZIP: ______________________

Phone: ____________ Fax____________ Contact Person: ____________ Contact's Phone: ____________

## 3 INSURANCE INFORMATION
Please fax copy of prescription and insurance cards with this form, if available (front and back)

## 4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: ________ Ship to: ☐ Patient ☐ Office ☐ Other: __________

**Diagnosis (ICD-10):**

☐ M06.9 Rheumatoid Arthritis, Unspecified
☐ L40.50 Arthropathic Psoriasis, Unspecified
☐ M08.00 Unspecified Juvenile Rheumatoid Arthritis of Unspecified Site
☐ M45.9 Ankylosing Spondylitis of Unspecified Sites in Spine
☐ L40.59 Other Psoriatic Arthropathy
☐ Other Code: ________ Description ______________

For additional ICD-10 information, please visit CVS Specialty Healthcare Professionals Website
https://www.cvsspecialty.com/wps/portal/specialty/healthcare-professionals/about-us

**Patient Clinical Information:**

Allergies: ______________________ Weight: ______lb/kg Height: ______in/cm TB Test Result: ____________ Date: ________

**Nursing:**

Specialty pharmacy to coordinate injection training/ home health infusion nurse visit necessary ☐ Yes ☐ No

Site of Care: ☐ MD office ☐ Infusion Clinic ☐ Outpatient Health ☐ Home Health

Injection training not necessary. Date training occurred: ____________

Reason: ☐ MD office training patient ☐ Pt already independent ☐ Referred by MD to alternate trainer

## 5 PRESCRIPTION INFORMATION

| MEDICATION | STRENGTH | DOSE & DIRECTIONS | QUANTITY/REFILLS |
|---|---|---|---|
| ☐ Actemra | ☐ 80 mg/4 mL<br>☐ 200 mg/10 mL<br>☐ 400 mg/20 mL | ☐ Induction Dose: Infuse 4 mg/kg every 4 weeks.<br>☐ Maintenance Dose: Infuse 8 mg/kg every 4 weeks.<br>☐ Other: ____________ | Quantity:______<br>Refills:________ |
| ☐ Actemra | 162mg/0.9 mL prefilled syringe | ☐ For patients weighing <100kg: Inject 162mg SC every other week, followed by an increase to every week based on clinical response<br>☐ For patients weighing ≥ 100kg: Inject 162mg SC every week. | Quantity:______<br>Refills:________ |

☐ Patient is interested in patient support programs

**STAMP SIGNATURE NOT ALLOWED**

Ancillary supplies and kits provided as needed for administration

## 6 PHYSICIAN SIGNATURE REQUIRED

PRODUCT SUBSTITUTION PERMITTED (Date)
X______________________________

DISPENSE AS WRITTEN (Date)
X______________________________

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.


CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.
Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.
This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. or one of its affiliates.
©2020 CVS Pharmacy, Inc. or one of its affiliates. 75-38703A 071620

# Medications A-C
# Rheumatology Enrollment Form
**(Avsola™Cimzia®,Cosentyx®)**

**Please complete Patient and Prescriber information**

Patient Name: ______________________________ Patient DOB: ______________________________

Prescriber Name: ___________________________ Prescriber Phone: ___________________________

## 5 PRESCRIPTION INFORMATION

| MEDICATION | STRENGTH | DOSE & DIRECTIONS | QUANTITY/REFILLS |
|---|---|---|---|
| ☐ Avsola | 100 mg vial | ☐Rheumatoid Arthritis Induction Dose: In conjunction with methotrexate Infuse IV at 3 mg/kg (Dose = _____mg) at weeks 0, week 2, week 6 and every 8 weeks thereafter.<br>☐ Rheumatoid Arthritis Maintenance Dose: Infuse 3 mg/kg every 8 weeks.<br>☐ Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose = _____mg) at weeks 0, week 2, week 6 and every 8 weeks thereafter.<br>☐ Psoriatic Arthritis Maintenance Dose: Infuse 5 mg/kg every 8 weeks.<br>☐ Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose = _____mg) at weeks 0, week 2, week 6 and every 6 weeks thereafter.<br>☐ Ankylosing Spondylitis Maintenance Dose: Infuse 5 mg/kg every 6 weeks.<br>☐ Other:______________________________ | Quantity:______<br># of 100 mg vial<br>Refills:________ |
| ☐ Cimzia | Cimzia Starter Kit<br>(6 prefilled syringes) | Induction Dose: 400 mg initially and at week 2 and 4, (given as 2 SC of 200 mg each) followed by 200 mg every other week; | Quantity: 1 Kit<br>Refills: 0 |
| ☐ Cimzia | ☐ 200mg/1 mL prefilled syringe<br>☐ 200mg vial | ☐ Maintenance Dose: Inject 200mg SC every OTHER week.<br>☐ Maintenance Dose: Inject 400mg SC every four weeks.<br>☐ Other:______________________________ | Quantity:______<br>Refills:________ |
| ☐ Cosentyx | ☐ Sensoready® pen 150 mg/mL injection<br>☐ Prefilled syringe 150 mg/mL injection | Psoriatic Arthritis with Coexistent Moderate to Severe Plaque Psoriasis<br>☐ Loading Dose: Inject 300 mg (two injections) SC at weeks 0, 1, 2, 3 and 4.<br>☐ Maintenance Dose: Inject 300 mg (two injections) SC every 4 weeks.<br>Other Psoriatic Arthritis or Ankylosing Spondylitis<br>☐ With Loading Dose: Inject 150 mg (one injection) SC at weeks 0, 1, 2, 3 and 4, and then every 4 weeks thereafter.<br>☐ Without Loading Dose: Inject 150 mg (one injection) SC every 4 weeks.<br>☐ Other:______________________________ | Quantity:_________<br>Refills:___________ |

☐ Patient is interested in patient support programs **STAMP SIGNATURE NOT ALLOWED** Ancillary supplies and kits provided as needed for administration

## 6 PHYSICIAN SIGNATURE REQUIRED

PRODUCT SUBSTITUTION PERMITTED (Date) DISPENSE AS WRITTEN (Date)

X______________________________ X______________________________

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.
Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.
This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. or one of its affiliates.
©2020 CVS Pharmacy, Inc. or one of its affiliates. 75-38703A 071620

# Medications E-I
# Rheumatology Enrollment Form
**(Enbrel®, Humira®, Ilaris®,Inflectra®)**

**Please complete Patient and Prescriber information**

Patient Name: ______________________________ Patient DOB: ______________________________

Prescriber Name: ____________________________ Prescriber Phone: ___________________________

## 5 PRESCRIPTION INFORMATION

| MEDICATION | STRENGTH | DOSE & DIRECTIONS | QUANTITY/REFILLS |
|---|---|---|---|
| ☐ Enbrel | ☐ 25mg/0.5 mL prefilled syringe<br>☐ 25mg vial<br>☐ 50mg/mL Sureclick™ Autoinjector<br>☐ 50mg/mL prefilled syringe<br>☐ 50 mg/mL Enbrel Mini™ prefilled cartridge for use with the AutoTouch™ reusable autoinjector only (Prescriber MUST supply). CVS does not order the autoinjector. | ☐ Inject 25mg SC TWICE a week (72 – 96 hours apart).<br>☐ Inject 50mg SC ONCE a week.<br>☐ Other: ______________________ | Quantity:_________<br>Refills:___________ |
| ☐ Humira | ☐ 40 mg/0.4 mL Pen **Citrate Free**<br>☐ 40 mg/0.4 mL Prefilled Syringe **Citrate Free** | ☐ Inject 40mg SC every OTHER week.<br>☐ Other: ______________________ | Quantity:_________<br>Refills:___________ |
| ☐ Ilaris | 150 mg/mL injection solution | For patients weighing ≥ 7.5 kg: Inject 4 mg/kg (with a maximum of 300 mg) SC every 4 weeks. Each single-dose vial of ILARIS (canakinumab) Injection delivers 150 mg/mL sterile, preservative-free, clear to slightly opalescent, colorless to a slight brownish to yellow solution. | Quantity:_________<br>Refills:___________ |
| ☐ Inflectra | 100 mg vial | ☐ Rheumatoid Arthritis Induction Dose: In conjunction with methotrexate Infuse IV at 3 mg/kg (Dose = _____mg) at weeks 0, week 2, week 6 and every 8 weeks thereafter.<br>☐ Rheumatoid Arthritis Maintenance Dose: Infuse 3 mg/kg every 8 weeks.<br>☐ Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose = _____mg) at weeks 0, week 2, week 6 and every 8 weeks thereafter.<br>☐ Psoriatic Arthritis Maintenance Dose: Infuse 5 mg/kg every 8 weeks.<br>☐ Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose = _____mg) at weeks 0, week 2, week 6 and every 6 weeks thereafter.<br>☐ Ankylosing Spondylitis Maintenance Dose: Infuse 5 mg/kg every 6 weeks.<br>☐ Other: ______________________ | Quantity:_________<br># of 100 mg vial<br>Refills:___________ |

☐ Patient is interested in patient support programs **STAMP SIGNATURE NOT ALLOWED** Ancillary supplies and kits provided as needed for administration

## 6 PHYSICIAN SIGNATURE REQUIRED

PRODUCT SUBSTITUTION PERMITTED (Date) DISPENSE AS WRITTEN (Date)

X______________________________________ X______________________________________

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.
Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.
This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. or one of its affiliates.
©2020 CVS Pharmacy, Inc. or one of its affiliates. 75-38703A 071620

# Medications K-O
# Rheumatology Enrollment Form
**(Kevzara®,Olumiant®,Orencia®, Otezla®)**

**Please complete Patient and Prescriber information**

Patient Name: ______________________________ Patient DOB: ______________________________

Prescriber Name: ______________________________ Prescriber Phone: ______________________________

## 5 PRESCRIPTION INFORMATION

| MEDICATION | STRENGTH | DOSE & DIRECTIONS | QUANTITY/REFILLS |
|---|---|---|---|
| ☐ Kevzara | ☐ 200 mg/1.14 mL prefilled syringe (pk of 2)<br>☐ 150 mg/1.14 mL prefilled syringe (pk of 2)<br>☐ 200 mg/1.14 mL prefilled pen (pk of 2)<br>☐ 150 mg/1.14 mL prefilled pen (pk of 2) | ☐ Inject 200 mg SC once every two weeks.<br>☐ Inject 150 mg SC once every two weeks. | Quantity:_________<br>Refills:___________ |
| ☐ Olumiant | ☐ 2 mg tablet<br>☐ 1 mg tablet | ☐ Take 2 mg PO once daily<br>☐ Other: ____________________________ | Quantity:__________<br>Refills:___________ |
| ☐ Orencia | ☐ 125mg prefilled syringe<br>☐ ClickJect Autoinjector 125 mg/mL pack of 4 | ☐ Inject 125mg SC every week<br>☐ After Single IV Loading Dose: Inject 125mg SC within a day and 125mg SC every week thereafter.<br>☐ Patients Unable to Receive an IV Loading Dose: Inject 125 mg SC every week.<br>☐ Patients Transitioning from IV Infusion Therapy: Inject 125 mg SC instead of the next scheduled IV dose, followed by 125mg SC injections every week thereafter. | Quantity:__________<br>Refills:___________ |
| ☐ Orencia | 250 mg vial | ☐ Infuse ___ mg at weeks 0, 2 and 4, then every 4 weeks thereafter.<br>☐ Other: ____________________________ | Quantity:__________<br>Refills:___________ |
| ☐ Otezla | Titration Starter Pack | Day 1: 10 mg PO in the morning.<br>Day 2: 10 mg PO in the morning and 10 mg PO in the evening.<br>Day 3: 10 mg PO in the morning and 20 mg PO in the evening.<br>Day 4: 20 mg PO in the morning and 20 mg PO in the evening.<br>Day 5: 20 mg PO in the morning and 30 mg PO in the evening.<br>Day 6 and thereafter: 30 mg PO twice daily. | Quantity: 1 Pack<br>Refills: 0 |
| ☐ Otezla | 30 mg tablet | ☐ Maintenance Dose: 30 mg PO twice daily.<br>☐ Other: ____________________________ | Quantity:__________<br>Refills:___________ |

☐ Patient is interested in patient support programs **STAMP SIGNATURE NOT ALLOWED** Ancillary supplies and kits provided as needed for administration

## 6 PHYSICIAN SIGNATURE REQUIRED

PRODUCT SUBSTITUTION PERMITTED (Date) DISPENSE AS WRITTEN (Date)

X______________________________________________ X______________________________________________

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.
Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. or one of its affiliates.
©2020 CVS Pharmacy, Inc. or one of its affiliates. 75-38703A 071620

# Medications R-S
# Rheumatology Enrollment Form
**(Remicade®, Renflexis®, Rinvoq®, Rituxan®, Simponi®)**

**Please complete Patient and Prescriber information**

Patient Name: ______________________________ Patient DOB: ______________________________

Prescriber Name: ___________________________ Prescriber Phone: ___________________________

## 5 PRESCRIPTION INFORMATION

| MEDICATION | STRENGTH | DOSE & DIRECTIONS | QUANTITY/REFILLS |
|---|---|---|---|
| ☐ Remicade | 100 mg vial | ☐ Rheumatoid Arthritis Induction Dose: In conjunction with methotrexate Infuse IV at 3 mg/kg (Dose = _____mg) at weeks 0, week 2, week 6 and every 8 weeks thereafter.<br>☐ Rheumatoid Arthritis Maintenance Dose: Infuse 3 mg/kg every 8 weeks.<br>☐ Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose = _____mg) at weeks 0, week 2, week 6 and every 8 weeks thereafter.<br>☐ Psoriatic Arthritis Maintenance Dose: Infuse 5 mg/kg every 8 weeks.<br>☐ Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose = _____mg) at weeks 0, week 2, week 6 and every 6 weeks thereafter.<br>☐ Ankylosing Spondylitis Maintenance Dose: Infuse 5 mg/kg every 6 weeks.<br>☐ Other: ______________________________ | Quantity:__________<br>Refills:___________ |
| ☐ Renflexis | 100 mg vial | ☐ Rheumatoid Arthritis Induction Dose: In conjunction with methotrexate Infuse IV at 3 mg/kg (Dose = _____mg) at weeks 0, week 2, week 6 and every 8 weeks thereafter.<br>☐ Rheumatoid Arthritis Maintenance Dose: Infuse 3 mg/kg every 8 weeks.<br>☐ Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose = _____mg) at weeks 0, week 2, week 6 and every 8 weeks thereafter.<br>☐ Psoriatic Arthritis Maintenance Dose: Infuse 5 mg/kg every 8 weeks.<br>☐ Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose = _____mg) at weeks 0, week 2, week 6 and every 6 weeks thereafter.<br>☐ Ankylosing Spondylitis Maintenance Dose: Infuse 5 mg/kg every 6 weeks.<br>☐ Other: ______________________________ | Quantity:_________<br># of 100 mg vial<br>Refills:___________ |
| ☐ Rinvoq | 15 mg | ☐ Take one 15 mg tablet PO once daily.<br>☐ Other: ______________________________ | Quantity:__________<br>Refills:___________ |
| ☐ Rituxan | ☐ 100 mg/10 mL vial<br>☐ 500 mg/50 mL vial | ☐ Infuse two doses of 1000 mg separated by 2 weeks.<br>☐ Other: ______________________________ | Quantity:__________<br>Refills:___________ |
| ☐ Simponi | ☐ 50mg/0.5mL prefilled SmartJect® Autoinjector<br>☐ 50mg/0.5mL prefilled syringe | ☐ Inject 50mg SC once a month.<br>☐ Other: ______________________________ | Quantity:__________<br>Refills:___________ |

☐ Patient is interested in patient support programs **STAMP SIGNATURE NOT ALLOWED** Ancillary supplies and kits provided as needed for administration

## 6 PHYSICIAN SIGNATURE REQUIRED

PRODUCT SUBSTITUTION PERMITTED (Date)

X______________________________________________

DISPENSE AS WRITTEN (Date)

X______________________________________________

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.
Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. or one of its affiliates.

# Medications S-Z
# Rheumatology Enrollment Form
**(Simponi ARIA®, Stelara®, Taltz®,Tremfya® ,Xeljanz®)**

**Please complete Patient and Prescriber information**

Patient Name: ______________________________ Patient DOB: ______________________________

Prescriber Name: ___________________________ Prescriber Phone: ___________________________

## 5 PRESCRIPTION INFORMATION

| MEDICATION | STRENGTH | DOSE & DIRECTIONS | QUANTITY/REFILLS |
|---|---|---|---|
| ☐ Simponi ARIA | 50 mg/4 mL in a single use vial | Infuse 2 mg/kg over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter. | Quantity:_________ # of 50 mg vial Refills:___________ |
| ☐ Stelara | ☐ 45mg/0.5mL prefilled syringe ☐ 90mg/mL prefilled syringe | ☐ For patients weighing ≤100 kg (220 lbs): Inject 45 mg SC initially and 4 weeks later, followed by 45 mg every 12 weeks. ☐ For patients weighing >100 kg (220 lbs): Inject 90 mg SC initially and 4 weeks later, followed by 90 mg every 12 weeks. ☐ Other: ______________________ | Quantity:__________ Refills:___________ |
| ☐ Taltz | ☐ 80 mg Single Dose Autoinjector ☐ 80 mg Single Dose Prefilled Syringe | Psoriatic Arthritis with Coexistent Moderate to Severe Plaque Psoriasis Dosing: ☐ Starting Dose: Inject SC two 80 mg injections on Day 1, then begin the induction dose 2 weeks later. ☐ Induction Dose: Inject SC one 80 mg injection every 2 weeks (weeks 2, 4, 6, 8, 10, and 12). ☐ Maintenance Dose: Inject SC one 80 mg injection every 4 weeks. | ☐ 3 Pens/Syringes ☐ 2 Pens/Syringes ☐1 Pens/Syringes Refills: ___________ |
| ☐ Taltz | ☐ 80 mg Single Dose Autoinjector ☐ 80 mg Single Dose Prefilled Syringe | Psoriatic Arthritis Dosing and Ankylosing Spondylitis Dosing: ☐ Starting Dose: Inject SC two 80 mg injections on Day 1. ☐ Maintenance Dose: Inject SC one 80 mg injection every 4 weeks. Non-radiographic Axial Spondyloarthritis Dosing: ☐ Dose: Inject SC one 80 mg injection every 4 weeks | Quantity: ☐ 2 Pens/Syringes ☐1 Pens/Syringes Refills:___________ |
| ☐ Tremfya | 100 mg/mL prefilled syringe | Psoriatic Arthritis Dosing: ☐ 100mg administered by SC at Week 0, Week 4 and every 8 weeks thereafter | Quantity:__________ Refills:___________ |
| ☐ Xeljanz | ☐ 5 mg Tablet ☐ 11 mg XR Tablet | ☐ Take one 5 mg tablet PO twice daily ☐ Take one 11 mg PO once daily ☐ Other:______________________ | Quantity:_________ Refills:___________ |

**Complete Items below, required for Home Infusion/Coram AIS:**

| MEDICATION/SUPPLIES | ROUTE | DOSE/STRENGTH/DIRECTIONS | QUANTITY/REFILLS |
|---|---|---|---|
| Catheter ☐ PIV ☐ PORT ☐ PICC | ☐ IV | Catheter Care/Flush – Only on drug admin days – SASH or PRN to maintain IV access and patency PIV – NS 5ml (Heparin 10 units/ml 3-5ml if multiple days) PORT/PICC – NS 10ml & Heparin 100units/ml 3-5ml, and/or 10ml sterile saline to access port a cath | Quantity:_________ Refills:___________ |
| ☐ Epinephrine **nursing requires** | ☐ IM ☐ | ☐ Adult 1:1000, 0.3mL (>30kg/>66lbs) ☐ Peds 1:2000, 0.3mL (15-30kg/33-66lbs) ☐ Infant 0.1mL/0.1mL, 0.1mL (7.5-15kg/16.5-33lbs) PRN severe allergic reaction – Call 911 May repeat in 5-15 minutes as needed | Quantity:_________ Refills:___________ |

☐ Patient is interested in patient support programs

**STAMP SIGNATURE NOT ALLOWED**

Ancillary supplies and kits provided as needed for administration

## 6 PHYSICIAN SIGNATURE REQUIRED

PRODUCT SUBSTITUTION PERMITTED (Date)

X________________________________________

DISPENSE AS WRITTEN (Date)

X________________________________________

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. or one of its affiliates.

©2020 CVS Pharmacy, Inc. or one of its affiliates. 75-38703A 071620